标题:Prognostic impact of elevation of vascular endothelial growth factor family expression in patients with non-small cell lung cancer: An updated meta-analysis
作者:Zheng C.-L.; Qiu C.; Shen M.-X.; Qu X.; Zhang T.-H.; Zhang J.-H.; Du J.-J.
作者机构:[Zheng, C.-L] Department of Thoracic Surgery, Provincial Hospital Affiliated to Shandong University, Shandong University, Jinan, China;[ Qiu, C] Insti 更多
通讯作者地址:Du, J.-J.; Department of Thoracic Surgery, Provincial Hospital Affiliated to Shandong University, Shandong UniversityChina
来源:Asian Pacific Journal of Cancer Prevention
出版年:2015
卷:16
期:5
页码:1881-1895
DOI:10.7314/APJCP.2015.16.5.1881
关键词:NSCLC; Prognosis; Vascular endothelial growth factor; Vascular endothelial growth factor receptor
摘要:Background: The vascular endothelial growth factor family has been implicated in tumorigenesis and metastasis. The prognostic value of each vascular endothelial growth factor family member, particular VEGF/ VEGFR co-expression, in patients with non-small lung cancer remains controversial. Materials and Methods: Relevant literature was identified by searching PubMed, EMBASE and Web of Science. Studies evaluating expression of VEGFs and/or VEGFRs by immunohistochemistry or ELISA in lung cancer tissue were eligible for inclusion. Hazard ratios (HRs) and 95% confidence intervals (CIs) from individual study were pooled by using a fixed- or random-effect model, heterogeneity and publication bias analyses were also performed. Results: 74 studies covering 7,631 patients were included in the meta-analysis. Regarding pro-angiogenesis factors, the expression of VEGFA (HR=1.633, 95%CI: 1.490-1.791) and VEGFR1 (HR=1.924, 95%CI: 1.220-3.034) was associated separately with poor survival. Especially, VEGFA over-expression was an independent prognostic factor in adenocarcinoma (ADC) (HR=1.775, 95%CI: 1.384-2.275) and SCC (HR=2.919, 95%CI: 2.060-4.137). Co-expression of VEGFA/VEGFR2 (HR=2.011, 95%CI: 1.405-2.876) was also significantly associated with worse survival. For lymphangiogenesis factors, the expression of VEGFC (HR=1.611, 95%CI: 1.407-1.844) predicted a poor prognosis. Co-expression of VEGFC/VEGFR3 (HR=2.436, 95%CI: 1.468-4.043) emerged as a preferable prognostic marker. Conclusions: The expression of VEGFA (particularly in SCC and early stage NSCLC), VEGFC, VEGFR1 indicates separately an unfavorable prognosis in patients with NSCLC. Co-expression VEGFA/ VEGFR2 is comparable with VEGFC/VEGFR3, both featuring sufficient discrimination value as preferable as p rognostic biologic markers.
收录类别:SCOPUS;SCOPUS
Scopus被引频次:8
最新影响因子:2.514
资源类型:期刊论文
原文链接:https://www.scopus.com/inward/record.uri?eid=2-s2.0-84928563400&doi=10.7314%2fAPJCP.2015.16.5.1881&partnerID=40&md5=4076361b3eac168acbd6ed812ef19979
TOP